NEWS
Ivonescimab in Combination With Chemotherapy Approved in China by Nmpa for 2L+ Egfrm Nsclc Based on Harmoni-a Clinical Trial: Positive Trend Observed in Overall Survival Towards Ivonescimab Plus Chemotherapy
Summit Therapeutics (NASDAQ: SMMT) has announced that its partner, Akeso, has received marketing authorization from China's National Medical Products Administration (NMPA) for ivonescimab in combination with chemotherapy for treating patients with EGFR-mutated non-squamous non-small cell lung cancer (NSCLC). This approval is based on the Phase III HARMONi-A clinical trial, which showed a significant improvement in progression-free survival (PFS) and a positive trend in overall survival (OS). Ivonescimab plus chemotherapy achieved a 54% reduction in disease progression risk compared to chemotherapy alone, with a median PFS of 7.1 months versus 4.8 months for the placebo group. The trial also reported a disease control rate of 93.1% for the combination therapy. Safety profile was manageable, with 5.6% of patients discontinuing ivonescimab due to adverse events. The positive results were presented at the 2024 ASCO Annual Meeting. Summit will host a conference call on June 3, 2024, to discuss these updates.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1077Followers
68Following
7428Visitors
Follow
StaNnnn : still been halted, why? Wait until Monday?
Jaguar8 OP StaNnnn : Likely